Inicio・Lista de Acciones・Zealand Pharma A-S

Zealand Pharma A-S

Cerrado

320.2 0.25

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

308

Máximo

324.2

Métricas clave
By Trading Economics
Ingresos	4.3B 3.9B
Ventas	4.5B 4.5B
P/B Media del Sector	8.036 57.371
BPA	55.34
Margen de beneficios	87.219
Empleados	578
EBITDA	4.2B 3.9B

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+25.15% upside

Dividendos
By Acuity
Próximas Ganancias	12 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-821M 21B
Apertura anterior	319.95
Cierre anterior	320.2

Zealand Pharma A-S Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 ago 2026, 23:51 UTC

Bitcoin and Ethereum rise amid broader financial trends, while concerns over U.S. national debt and rising bond yields prompt Treasury interventions ahead of key economic data releases.

23 ago 2026, 23:51 UTC

Bitcoin and Ethereum rise amid concerns over U.S. national debt and bond market pressures, while Asian stocks anticipate recovery following positive U.S. market performance.

23 ago 2026, 23:51 UTC

Bitcoin and Ethereum rise as U.S. national debt hits $40 trillion, prompting concerns over economic stability and upcoming key economic data releases.

23 ago 2026, 23:51 UTC

Cryptocurrency prices rise amid U.S. national debt concerns and bond market volatility, as investors brace for major earnings reports and geopolitical tensions.

23 ago 2026, 23:51 UTC

Australia's Construction Output Expected to Rise 0.4% Amid Cautious Investor Sentiment Ahead of August Release

23 ago 2026, 23:51 UTC

Australia's RBA Trimmed Mean CPI Release on August 26, 2026, Expected to Reveal Key Insights into Core Inflation Trends Amid Global Economic Uncertainty.

23 ago 2026, 23:51 UTC

Australia's Inflation Rate Expected to Drop Slightly to 3.2% Amid Economic Shifts and Market Volatility Concerns

23 ago 2026, 23:51 UTC

Macro News

Bitcoin is higher today, continuing its upward trend since Saturday. Positive sentiment follows Wall Street's rebound amid declining interest rates and rising gold prices.

23 ago 2026, 23:51 UTC

Japan's Industrial Production Data Release on August 30 Expected to Show Continued Growth Amid Market Concerns.

23 ago 2026, 23:51 UTC

Japan's Retail Sales YoY Data Release on August 30 Expected to Show Significant Rebound Amid Mixed Economic Sentiment and Recent Stock Market Decline.

23 ago 2026, 23:41 UTC

Canada's Monthly GDP Growth Expected Amid Trade Tensions and Inflation Concerns Ahead of August 28 Release.

23 ago 2026, 23:41 UTC

Bank of Korea's Upcoming Interest Rate Decision Sparks Optimism Amid KOSPI Rally and Global Economic Trends

23 ago 2026, 23:41 UTC

Canada's GDP Growth Rate Faces Caution Amid Escalating U.S. Trade Tensions and Tariff Concerns Ahead of August 28 Release

23 ago 2026, 23:41 UTC

Canada's Q2 2026 GDP Growth Rate Release Amidst U.S. Trade Tensions and Infrastructure Boosts Scheduled for August 28, Heightening Market Scrutiny.

23 ago 2026, 23:31 UTC

RBA Bulletin Release on August 27, 2026 Sparks Anticipation Amid Global Decline in Interest Rates and Market Fluctuations.

23 ago 2026, 23:21 UTC

Upcoming U.S. Retail Inventories Ex Autos Data Release on August 27, 2026, Amid Mixed Sentiment and Economic Growth Concerns

23 ago 2026, 23:21 UTC

U.S. Goods Trade Balance Expected to Hit $99 Billion Deficit Amid Rising U.S.-Canada Tariff Tensions

23 ago 2026, 23:21 UTC

U.S. Wholesale Inventories Expected to Rise 0.1% in July Amid Mixed Market Sentiment Ahead of August Release

23 ago 2026, 23:21 UTC

Canada's Current Account Deficit Expected to Reach -5.5 Billion CAD in Q2 2026 Amid Trade Tensions with U.S.

23 ago 2026, 23:21 UTC

The CAD/CHF currency pair is lower during after-market hours, reflecting a decline since Friday's close amid notable fluctuations in its one-month trading range.

23 ago 2026, 23:21 UTC

Correlated Moves

XRP is rising during Sunday’s session, supported by Bitcoin's upward movement. The asset has gained significantly since Saturday and remains above its 20-day moving average.

23 ago 2026, 23:11 UTC

EUR/NZD is trading higher in after-market hours, continuing a gradual increase since Friday's close, despite a recent trend of lower closes.

23 ago 2026, 23:11 UTC

U.S. Home Prices Expected to Rise 1.7% YoY Amid Inflation and Economic Uncertainty, According to S&P/Case-Shiller Index

23 ago 2026, 23:11 UTC

U.S. GDP Price Index QoQ 2nd Estimate Set for August 26, Forecasting a 0.063% Increase Amid Inflation Concerns and Mixed Market Sentiment

23 ago 2026, 23:11 UTC

South Africa's Trade Balance Data Release on August 28 Expected Amid Fluctuating Trends and Commodity Market Sentiment.

23 ago 2026, 23:01 UTC

Correlated Moves

Gold/Silver is trading lower, influenced by broader market sentiment and concerns over the U.S. national debt reaching $40 trillion. It remains below its 20-day moving average.

23 ago 2026, 23:01 UTC

Gold/NZD is trading higher since Friday's close, maintaining a position above its 20-day moving average amid concerns over the U.S. national debt reaching $40 trillion.

23 ago 2026, 23:01 UTC

Gold/JPY is trading higher, reflecting a broader positive performance. The asset remains significantly above its 20-day moving average, indicating strong underlying momentum.

23 ago 2026, 23:01 UTC

Gold/HKD is higher today, reflecting a strong trend above its 20-day moving average. Earlier, it reached a high of 2.16% above Friday's close.

23 ago 2026, 23:01 UTC

Gold/SGD is higher in the current session, maintaining a gain above its 20-day moving average despite a slight pullback from earlier peaks.

Comparación entre iguales

Cambio de precio

Zealand Pharma A-S previsión

Precio Objetivo

By TipRanks

25.15% repunte

Estimación a 12 Meses

Media 270.582 DKK 25.15%

Máximo 270.568 DKK

Mínimo 270.568 DKK

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Zealand Pharma A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Zealand Pharma A-S Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Otras acciones del sector

NOVO.B.DK

Novo Nordisk A-S (Class B)

302.35

↑ +1.04%

GMAB.DK

Genmab A-S

2,115

↓-1.76%

Zealand Pharma A-S

Resumen

Variación precio

Métricas clave

Recomendaciones

Dividendos

Estadísticas de Mercado

Zealand Pharma A-S Gráfico

Noticias Relacionadas

Comparación entre iguales

Zealand Pharma A-S previsión

Precio Objetivo

Consenso

Finanzas

Acerca de Zealand Pharma A-S

Otras acciones del sector